[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100458923":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":29,"centralContacts":33,"locations":38,"responsibleParty":58,"collaborators":21,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":21,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":21,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":21,"overallStatus":41,"whyStopped":21,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Zhongnan Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-pentixafor and 18F-FDG PET\u002FCT","EXPERIMENTAL","Patients with a high clinical suspicion of, or confirmed newly diagnosed or relapsed hematological malignancies will be recruited. All enrolled patients will undergo both 68Ga-pentixafor and 18F-FDG PET\u002FCT imaging within two weeks.",[13,14],"Drug: 68Ga-pentixafor","Device: PET\u002FCT",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","68Ga-pentixafor","All participants undergo intravenous administration of 68Ga-pentixafor (1.85-3.71 MBq\u002Fkg body weight).",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DEVICE","PET\u002FCT","PET\u002FCT imaging is performed 1 h after intravenous injection of 68Ga-pentixafor.",[9],[28],"Positron Emission Tomography\u002FComputed Tomography",[30],{"name":31,"affiliation":5,"role":32},"Yong He, MD, PhD","PRINCIPAL_INVESTIGATOR",[34],{"name":31,"role":35,"phone":36,"phoneExt":21,"email":37},"CONTACT","+86-27-67812698","vincentheyong@163.com",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Zhongnan Hospital of Wuhan University","RECRUITING","Wuhan","Hubei","430071","China","CN",{"type":48,"coordinates":49},"Point",[50,51],114.26667,30.58333,{"lat":51,"lon":50},[54,57],{"name":55,"role":35,"phone":56,"phoneExt":21,"email":21},"Lei Zheng","+86-27-67812787",{"name":31,"role":32,"phone":21,"phoneExt":21,"email":21},{"type":32,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"Yong He","Principal Investigator","100458923","cxcr4-targeted-petct-imaging-in-hematological-malignancies-100458923",false,"NCT05255926","CXCR4-targeted PET\u002FCT Imaging in Hematological Malignancies","An Exploratory, Open-Label, Single Center Study of CXCR4-targeted PET\u002FCT Imaging for Evaluation of Hematological Malignancies","Inclusion Criteria:\n\n1. Volunteer to participate and sign an informed consent form;\n2. 18 ≤ Age ≤ 90 years;\n3. Patients with highly suspected, or newly diagnosed, or relapsed hematological malignancies;\n4. Willing and able to follow schedule visits, treatment plans and laboratory tests.\n\nExclusion Criteria:\n\n1. pregnancy or breastfeeding;\n2. Allergic to CXCR4-targeted tracers or excipients;\n3. Fasting blood glucose level exceeded 11.0 mmol\u002FL prior to injection of 18F-FDG;\n4. Those who cannot complete PET\u002FCT scan, including inability to keep supine, claustrophobia, radiation phobia, etc.;\n5. Researchers think it is inappropriate to participate in this clinical trial for patients with poor compliance or other unsuitable factors.","ALL","18 Years","90 Years",{"count":72,"type":73},300,"ESTIMATED","INTERVENTIONAL",[76],"NA","Hematological malignancies continue to pose significant clinical challenges due to their high incidence, heterogeneous biology, and substantial mortality. Although 18F-FDG PET\u002FCT remains the most commonly used molecular imaging modality, its limited specificity can result in false-positive or false-negative findings, especially in indolent or low-metabolism subtypes, thereby hampering accurate diagnosis, staging, and therapeutic evaluation. C-X-C chemokine receptor type 4 (CXCR4) is frequently overexpressed in a broad spectrum of hematologic malignancies and correlates with aggressive disease and unfavorable outcomes. CXCR4-targeted molecular imaging using \\^68Ga-pentixafor PET\u002FCT has shown promise for improved disease characterization. This prospective study aims to systematically compare 68Ga-pentixafor PET\u002FCT with 18F-FDG PET\u002FCT in terms of diagnostic performance, staging accuracy, risk stratification, and prognostic relevance in patients with hematological malignancies. Furthermore, the study will incorporate artificial intelligence-based image analysis to enhance lesion detection, automate quantitative assessments, and support personalized clinical decision-making.",[79,24,80],"CXCR4","Hematological Malignancy","2025-06-22",{"date":83,"type":84},"2025-06-26","ACTUAL",{"date":86,"type":84},"2022-03-01",{"date":88,"type":73},"2026-12-31",{"name":5,"class":6},1]